Cure My Disease

Don't miss your cure!

 Log in / Sign up

New MRI techniques could spare men from unnecessary prostate biopsies

NCT ID NCT07808528

Diagnosis Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers are testing three advanced diffusion MRI sequences to see which one best identifies men who can safely skip a prostate biopsy. The study includes men with suspicious prostate MRI results and those already scheduled for a routine MRI. By comparing these new scans against standard MRI, the team aims to reduce the number of unnecessary biopsies, which carry risks and discomfort.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
advanced diffusion MRI scans (VERDICT, fast-VERDICT, and RSI)
What this could lead to
If one of these advanced MRI methods proves more accurate, doctors could use it to help men with suspicious prostate scans avoid an unnecessary biopsy.
What could go wrong
The study is still in its validation phase, and the advanced scans may not prove accurate enough to replace or reduce biopsies. MRI results can also vary between scanners, which the study is trying to correct.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 660 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jan 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥18 scheduled for a prostate mpMRI (Optional Component) * Willing and able to provide written informed consent (Optional Component, Component 1 and Component 2) * Patients aged ≥18 with a prior mpMRI demonstrating at least one definite lesion suspicious for prostate cancer (Likert or PI-RADS score 4 or 5) and either under active surveillance for previously diagnosed low-risk prostate cancer or awaiting definitive treatment (Component 1) * Willing and able to undergo multiple MRI scans at different hospitals (Component 1) * Patients aged ≥18 with clinical suspicion of prostate cancer, who are scheduled for or have just undergone a prostate mpMRI as part of initial diagnostic workup (Component 2) Exclusion Criteria: * Contraindications to MRI (Optional Component, Component 1 and Component 2) * Inability to provide informed consent (Optional Component, Component 1 and Component 2) * Prostate biopsy within the last 3 months (Component 1) OR prior prostate cancer diagnosis or treatment (Component 2) * Inability to travel to partner hospital site (Component 1) * Contraindication to biopsy (Component 2)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer (diagnosis) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer (diagnosis)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University College London Hospitals NHS Foundation Trust

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.